Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

Gettinger, Scott; Horn, Leora; Gandhi, Leena; R. Spigel, David; Antonia, Scott; A. Rizvi, Naiyer; D. Powderly, John; S. Heist, Rebecca; D. Carvajal, Richard; M. Jackman, David; V. Sequist, Lecia; C. Smith, David; D. Leming, Philip; P. Carbone, David; Pinder-Schenck, Mary; L. Topalian, Suzanne; Stephen Hodi, F.; A. Sosman, Jeffrey; Sznol, Mario; F. McDermott, David; M. Pardoll, Drew; Sankar, Vindira; M. Ahlers, Christoph; Salvati, Mark; M. Wigginton, Jon; D. Hellmann, Matthew; Kollia, Georgia; Gupta, Ashok; R. Brahmer, Julie

doi:10.1200/jco.2014.58.3708

Public

Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

Published in Journal of Clinical Oncology • Apr 21, 2015

Authors:

Scott Gettinger

Leora Horn

Leena Gandhi

Abstract

PURPOSE: Programmed death 1 is an immune checkpoint that suppresses antitumor immunity. Nivolumab, a fully human immunoglobulin G4 programmed death 1 immune checkpoint inhibitor antibody, was active and generally well tolerated in patients with advanced solid tumors treated in a phase I trial with e...

Subject

Nivolumab

Medicine

Antibody

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!